Articles from Longhorn Vaccines and Diagnostics

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data at the World Vaccine Congress 2025 on LHNVD-303, the company's composite peptide vaccine for sepsis due to bacterial infections and its applications in inflammatory diseases. The World Vaccine Congress took place in Washington, D.C. from April 22-24.

Longhorn Vaccines and Diagnostics, a One Health company developing treatments and diagnostic tools for global public health and zoonosis concerns, will present new data from universal influenza pipeline candidates during two poster sessions at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2025. Longhorn will also be available at booth C108 in Hall B to discuss its differentiated approach to the world’s most critical infectious diseases in humans and animals. ESCMID 2025 is taking place in Vienna, Austria from April 11-15, 2025.

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today honors World Tuberculosis (TB) Day 2025 by reaffirming its commitment to ending TB globally through PrimeStore® MTM, the only FDA-cleared sample collection and transport device. PrimeStore enables safer, more accurate, and cost-effective TB sample collection and transport, thereby expanding access to high-quality sample collection methods, ensuring laboratory accuracy, and driving earlier TB detection, better treatment outcomes, and stronger global disease control efforts.

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, provided an update on the company's year-to-date progress, highlighting significant accomplishments supporting its commitment to advancing sample collection technology for infectious diseases, and enhancing global health diagnostics and vaccines.

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present three abstracts at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2024. ECCMID will take place online and in-person in Barcelona, Spain, from April 27-30, 2024.

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, is presenting a poster at World Vaccine Congress all day April 2-4, 2024 on a mice study that examined LHNVD-110, a novel, unconjugated single peptide vaccine comprised of multiple epitopes to broadly target human and influenza viruses. World Vaccine Congress is taking place April 1-4 in Washington, DC.

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data from an animal study indicating the durability and broad strain coverage of LHNVD-105, the company’s universal influenza vaccine candidate. The data was presented at IDWeek 2023, which took place in Boston from October 11-15, 2023.

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global animal and public health, announced today new data from the USDA National Veterinary Services Laboratory validating the company’s core diagnostic product, PrimeStore® Molecular Transport Medium (PS-MTM), and its potential to inactivate highly consequential livestock and poultry viruses to support safer and more effective diagnostic testing. The results of this study may be utilized by diagnostic testing laboratories for highly pathogenic agents affecting animal and human populations to revise guidance for select agent diagnostic testing and shipment of infectious substances. The data were published in a recent preprint publication of bioRxiv.

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today presented new data from an animal study showing that LHNVD-201, the company’s unconjugated peptide vaccine candidate, generated broad and durable neutralizing antibodies against Covid-19 and influenza viruses. Study results were presented at the 17th Vaccine Congress, taking place in Glasgow, Scotland from September 24-27, 2023.

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present new data from an animal study that examined the durability and broad strain coverage of LHNVD-201, an unconjugated peptide vaccine developed to mitigate co-infections with influenza and SARS-CoV-2 (Covid-19), at the 17th Vaccine Congress. The 17th Vaccine Congress will take place in-person in Glasgow, Scotland from September 24-27, 2023.

Longhorn Vaccines & Diagnostics, a privately held biotechnology company developing molecular-based collection and testing reagents, today announced milestone study results in The Journal of Applied Laboratory Medicine from the American Association for Clinical Chemistry (Oxford Academia). The research article, “Rapid and Safe Detection of SARS-CoV-2 and Influenza Virus RNA Using Onsite qPCR Diagnostic Testing from Clinical Specimens Collected in Molecular Transport Medium,” is the first published study to bridge the PrimeStore Molecular Transport Medium® (MTM), an FDA cleared collection device, with Roche’s cobas Liat®, a point-of-care FDA approved diagnostic system for simultaneous detection of SARS-CoV-2 (COVID-19) and influenza A/B viruses.